$TRMR is hypergrowth at unreasonably-low-price? #TRMR
Future looks bright, though past, a bit murky. Adtech, esp CTV/vid is on fire. Better numbers at far lower val than comps. A no-brainer with hair? $trmr #trmr
Many great threads & insights on fintwit, esp by @Yield_Fanatic Me, I am just trying to avoid overthinking great numbers. $trmr #trmr
Many in the space prefer $MGNI bec think better business. I am am not so sure. Put my chips on $TRMR, and we shall see.
Love it. Needham publishes $TRMR research w/ a math error claiming “premium” (double-the-actual) valuation is justified. LOL. After corrected by @Yield_Fanatic does NOT change the original targets.👀👀
$TRMR at 1/10th the valuation of TTD, faster growth and better margins. Also, higher % of revenue from CTV (A market for which TTD has been anointed with a 100x multiple)
$TRMR is a GULP
$TRMR is too risky at $22 now, but wont' be at $60 before long. #MrMarketLogic
$TRMR largest shareholder, Mithaq, raises stake from 21% to 22%. But what do they know.
Is $RFL the next Jonas StraightPath-like home run? Two cancer drugs in expedited-FDA-review status for a Q1 decision. Market size for Pancreatic approval alone could 10x the stock. 65%-approval chance each (FDA stats.) More Jonas magic possible? Or could be nothing....
$RFL$22/sh now. $200-$3,000 possible
- if Pancreatic drug approved this quarter (65% odds) & likely becomes standard of care.
- A typical Jonas set up. (I recall Net2phone $ Straightpath.)
With two fast-tracked drugs for FDA approval, 65% chance each this quarter, the EV on this one seems off-the-chart $RFL